Summary EXAS is on a huge rally due to Pfizer deal. The deal is a result of weakness though, not strength. I still believe EXAS makes it to $100/share in the next few years, but the easy money has been made. EXAS is at the top of trading range and […]
Hello, your membership does not give you access to this page.